- Libyan coast guard rescues more than 250 migrants trying to reach Ital
- It looks like tax reform is already paying off with the GOP base
- Thousands of Romanians mourn former king Michael
- Sexual harassment allegations swirl around ESPN
- Report: Toronto billionaire and his wife found dead in their home
- Austrian conservatives bring far right into government
- Russian and French foreign ministers discussed situation in Syria
- Australian PM future safeguarded in crucial Sydney by-election
- Palestinian billionaire Masri detained in Saudi Arabia: sources
- Myanmar journalists' group to don black T-shirts over arrest of Reuter
- Dustin Hoffman accused of sexual assault
- Facebook worries it might be bad for you, adds a mute button
- U.S. says did everything possible to help Italy cyber investigation
- Thai tour guide arrested for inappropriate behavior at Buddhist temple
- Roche, Shire court fight escalates over haemophilia drug
- Strong quake hits Indonesia's Java, kills three
- Strong quake hits Indonesia's Java, killed three
- Strong earthquake strikes Indonesia; 3 dead
- Peru's President to face impeachment proceedings
- Kurz's Austrian conservatives bring far right into government
Interview: Roche to seize leap-frog opportunity in lung cancer
LONDON (Reuters) - After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer.
“We have a real chance to be at the forefront here,” Chief Executive Severin Schwan said on Wednesday. “Our ambition is to become a clear leader in the field of cancer immunotherapies.”
At the same time he warned many investors would lose money across the industry as a large proportion of the hundreds of cancer trials now underway failed, leaving just a few winners.
His optimism for Roche has been buoyed by study results showing its immune-boosting medicine Tecentriq given with chemotherapy and the older drug Avastin significantly cut the risk of lung cancer worsening.
Researchers will detail the scale of that benefit, versus chemotherapy and Avastin alone, in a keenly awaited presentation at a medical meeting in Geneva on Thursday.
“We have the potential to get into the lead in first-line lung cancer,” Schwan said. “In all likelihood we have a medicine here that will potentially change the standard of care ... but we will also have to see how it compares with other therapies.”
Overall survival (OS) data will also be crucial in determining the ultimate winner in lung cancer - by far the biggest oncology market - since one of the main benefits of using immunotherapy is its long-lasting effects.
Roche does not yet have that OS data but initial observations are “encouraging” and it expects results in the first half of 2018, well ahead of OS findings with a competing drug combination including chemotherapy from Merck & Co.
Schwan needs Tecentriq to be a success to help replace revenue from older biological cancer drugs whose patents have expired or will shortly, exposing them to cheaper so-called biosimilar competition.
“On the pipeline side, we’re even more de-risked than a year ago ... but there is no doubt that the impact from biosimilars will be significant,” Schwan told Reuters.
“On balance, I‘m now very confident that we should be able to compensate for this erosion.”
Reporting by Ben Hirschler; editing by Alexander Smith
Our Standards:The Thomson Reuters Trust Principles.